Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] (NCT05536973)
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
🩺 Plain-English Summary (8th-Grade Level)
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Who can join: Review the eligibility criteria below.
Location: Adverum Clinical Site 178 — Phoenix, Arizona
Age range: 50 Years
🧪 Interventions in This Study
- ADVM-022 (GENETIC)
- ADVM-022 (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- Adverum Clinical Site 178 — Phoenix, Arizona
- Adverum Clinical Site 126 — Phoenix, Arizona
- Adverum Clinical Site 159 — Tucson, Arizona
- Adverum Clinical Site 100 — Beverly Hills, California
- Adverum Clinical Site 172 — Encino, California
- Adverum Clinical Site 169 — Fullerton, California
- Adverum Clinical Site 170 — Pasadena, California
- Adverum Clinical Site 174 — Poway, California
- Adverum Clinical Site 164 — Riverside, California
- Adverum Clinical Site 166 — Sacramento, California
- Adverum Clinical Site 175 — Santa Barbara, California
- Adverum Clinical Site 116 — Lakewood, Colorado
- Adverum Clinical Site 165 — Waterford, Connecticut
- Adverum Clinical Site 124 — Deerfield Beach, Florida
- Adverum Clinical Site 176 — Fort Lauderdale, Florida
- Adverum Clinical Site 168 — Jacksonville, Florida
- Adverum Clinical Site 149 — ‘Aiea, Hawaii
- Adverum Clinical Site 167 — Detroit, Michigan
- Adverum Clinical Site 161 — Royal Oak, Michigan
- Adverum Clinical Site 163 — Southaven, Mississippi
- Adverum Clinical Site 177 — Omaha, Nebraska
- Adverum Clinical Site 119 — Reno, Nevada
- Adverum Clinical Site 146 — Cherry Hill, New Jersey
- Adverum Clinical Site 171 — Teaneck, New Jersey
- Adverum Clinical Site 122 — West Columbia, South Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neovascular Age-related Macular Degeneration
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Arcadia, California
- A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) — Beverly Hills, California
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Gilbert, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD — Glendale, California
Explore by condition: All Neovascular Age-related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.